Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

• A transcriptomic-based model associated with PARP inhibitor sensitivity and immunogenic signatures in ovarian cancer.

  PMID 42014663 · PMC13230468 · Discover oncology · 2026 · 8 claims · 8 setups

  Full-text index only

  A 23-gene PARPi-sensor transcriptomic model stratifies ovarian cancer patients into high- and low-risk groups with significantly different overall survival, validated in TCGA and ICGC cohorts

  pdx tcga prognostic tcia bulk non-negative univariate

• SMARCA4/2 loss reduces BCL-xL expression and confers a druggable MCL1 dependency in cancer.

  PMID 41807550 · PMC13249849 · NPJ precision oncology · 2026 · 8 claims · 8 setups

  Full-text index only

  MCL1 inhibition is synthetic lethal with SMARCA4/2 loss in SCCOHT and NSCLC cells

  nsclc lung smarca4 bin-67 genome-wide drug colony

• Single-cell resolution of an open chromatin signature in persister tumor cells.

  PMID 41485222 · PMC12978573 · Cell reports · 2026 · 8 claims · 8 setups

  Full-text index only

  Single-nucleus multi-omic (snRNA-seq + snATAC-seq) profiling of fallopian tube, treatment-naive, and NACT-treated HGSOC tissue identifies a persister cell signature (PCS) defining the chemotherapy-tolerant state.

  non-malignant same epithelial tumor single-nucleus mitochondrial copy-number